메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
김수영 (아주대학교병원)
저널정보
대한갑상선-내분비외과학회 The Journal of Endocrine Surgery Journal of Endocrine Surgery 제24권 제3호
발행연도
2024.9
수록면
49 - 55 (7page)
DOI
10.16956/jes.2024.24.3.49

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
The fifth edition of the World Health Organization (WHO) histological classification of thyroid neoplasms released in 2022 includes newly recognized tumor types, subtypes, and a grading system. The term “oncocytic thyroid carcinoma” (OTC) is used in the new WHO classification to refer to invasive malignant follicular cell neoplasms composed of at least 75% oncocytic cells in which the nuclear features of papillary thyroid carcinoma and high-grade features are absent. As there are no reliable preoperative or intraoperative markers to identify OTC, diagnostic surgery is indicated when OTC is suspected. As the diagnosis of OTC is made postoperatively, the histopathological diagnosis frequently raises the question of completion surgery. The National Comprehensive Cancer Network (NCCN) guidelines only recommend the completion of thyroidectomy for invasive cancer (widely invasive or encapsulated angioinvasion with ≥4 vessels). In other cases, such as the encapsulated angioinvasive type with <4 vessels or minimally invasive oncocytic carcinoma, disease monitoring is preferred. Given the low rate of lymph node metastases, the benefit of routine prophylactic central lymph node dissection remains unclear, especially in the absence of vascular invasion from the primary tumor. Data regarding treatment efficacy for metastatic OTC are limited. However, trials with systemic therapy with targeted kinase inhibitor therapy support the use of sorafenib and lenvatinib.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

최근 본 자료

전체보기

댓글(0)

0